BioNexus Gene Lab Corp. Files 8-K
Ticker: BGLC · Form: 8-K · Filed: Jul 30, 2025 · CIK: 1737523
| Field | Detail |
|---|---|
| Company | Bionexus Gene Lab CORP (BGLC) |
| Form Type | 8-K |
| Filed Date | Jul 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, SEC Filing, Regulation FD
TL;DR
BioNexus Gene Lab Corp. filed a routine 8-K on 7/30/25. No major news.
AI Summary
BioNexus Gene Lab Corp. filed an 8-K on July 30, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, incorporated in Wyoming, has its principal executive offices in Kuala Lumpur, Malaysia. This filing does not appear to contain specific transactional or financial details beyond its routine reporting nature.
Why It Matters
This 8-K filing indicates routine corporate reporting by BioNexus Gene Lab Corp. to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for Regulation FD disclosure and financial statements, with no indication of significant events or material changes.
Key Numbers
- 001-41750 — SEC File Number (Company's SEC filing identifier)
- 251164692 — Film Number (SEC film identifier for the filing)
Key Players & Entities
- BioNexus Gene Lab Corp. (company) — Filer
- Wyoming (jurisdiction) — State of Incorporation
- Kuala Lumpur (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a Current Report for BioNexus Gene Lab Corp., primarily for Regulation FD Disclosure and to include Financial Statements and Exhibits.
When was this report filed?
The report was filed as of July 30, 2025.
Where is BioNexus Gene Lab Corp. incorporated?
BioNexus Gene Lab Corp. is incorporated in Wyoming.
What is the company's principal executive office address?
The principal executive offices are located at Unit A-28-7, Tower A, Menara UOA Bangsar, No.5 Jln Bangsar Utama 1, 59000 Kuala Lumpur.
Does this filing indicate any specific business developments or financial results?
The filing indicates it is for Regulation FD Disclosure and Financial Statements and Exhibits, but does not detail specific business developments or financial results within the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 30, 2025 regarding BioNexus Gene Lab Corp (BGLC).